Andelyn Biosciences

Happy Thanksgiving from all of us at Andelyn Biosciences! This season, we’re grateful for the incredible partners, patients, and team members who inspire our work every day. Together, we’re advancing gene therapies that transform lives and bring hope to families worldwide. Wishing you a day filled with joy, gratitude, and connection. #AndelynBiosciences #Thanksgiving #Gratitude #GeneTherapy

Scaling suspension processes for AAV-based gene therapies is no easy feat. From transitioning platforms to scaling for commercial success, the challenges are complex—but solvable. At Andelyn Biosciences, we leverage a Design of Experiments (DoE) approach to tackle these hurdles. Our process integrates state-of-the-art technologies with a data-driven strategy, enabling optimized production from flask to full-scale manufacturing. Curious about the technical details driving scalable AAV manufacturing? Sign up for our email newsletter to stay informed on:
- Comprehensive optimization techniques
- Data-driven scaling strategies
- Insights into factors like cell density, DNA ratios, and chromatography Join the conversation shaping the future of gene therapy manufacturing. Sign up here: https://buff.ly/3ZRv6zl #AndelynBiosciences #AAVCuratorPlatform #GeneTherapy #AAVManufacturing #Innovation #CDMO

We are proud to collaborate with Hubble Therapeutics in the fight against Leber Congenital Amaurosis 16 (LCA16), a devastating early-onset retinal disease leading to blindness. Through the power of our AAV Curator™ Platform, we’re optimizing and scaling the HUB-101 process to deliver clinical-grade AAV vectors designed to restore vision by targeting the underlying genetic cause. Together, we’re bringing hope to families impacted by ultra-rare diseases, advancing science, and redefining what’s possible in gene therapy. Learn more about our AAV Curator™ Platform here: https://buff.ly/4fdrqwO #AndelynBiosciences #AAVCuratorPlatform #GeneTherapy #AAVManufacturing #RareDiseases #InnovationForImpact #CDMO

At Andelyn Biosciences, we believe in the power of experience, know-how, and precision. Our modern facilities, designed for today’s highest quality rigor, and team of seasoned scientists are at the forefront of AAV gene therapy, offering reliable expertise in process development and cGMP manufacturing. Start working with us with a small-scale feasibility study and generate the data to drive decisions for your critical roadmap to clinical and commercial manufacturing. Learn more about our feasibility study offer here https://buff.ly/3A0hTJT #AndelynBiosciences #GeneTherapy #CDMO

The path to advancing healthcare through gene therapy is both exciting and complex. At Andelyn Biosciences, we’re not just part of this journey; we’re leading the way with expertise and reliable manufacturing. Whether you are in need of tech transferring the manufacturing of your program or looking for development and scale up into Andelyn’s AAV Curator™ Platform, let us work together to shape a hopeful future for patients in need of life-altering therapies. Learn more about our feasibility studies as a first step into a partnership defined by expertise and close collaboration. https://buff.ly/3A0hTJT #AndelynBiosciences #GeneTherapy #CDMO #AAVCuratorPlatform

Looking to enhance your tech transfer process with effective comparability strategies? At Andelyn Biosciences, we understand that establishing a clear path for comparability is crucial for successful tech transfer. Our team collaborates closely with clients to craft and execute analytical comparability protocols and acceptance criteria tailored to each program’s unique needs. Our featured white paper highlights the critical steps for achieving equivalence and maintaining quality across facilities, including: – Collaborative protocol drafting – Leveraging extensive analytical capabilities – A stepwise approach to assess essential product attributes Sign up for our email newsletter for more featured content and stay updated on insights into tech transfer strategies. Let us help you bridge the gap with our proven comparability expertise. https://buff.ly/3ZRv6zl #AndelynBiosciences #GeneTherapy #TechTransfer #Comparability #CDMO

Our journey began at Nationwide Children's Hospital, leading to the discovery of the first FDA-approved systemic gene therapy. Today, we stand ready as your reliable partner, equipped with the expertise and scalable solutions to bring your therapies from concept to commercialization. Get in touch and discover how we can contribute to your long-term success with a low risk feasibility study: https://buff.ly/3UzqzNP #andelynbiosciences

At Andelyn Biosciences, we’re passionate about accelerating gene therapy innovation. Our AAV Curator Platform’s modular approach is configurable, optimized to your process requirements, and reinforced with data and analytics. Whether you're a researcher or developer in the gene therapy field, this platform is crafted to support your journey from concept to clinic. Let’s push the boundaries of what’s possible—together. Visit our website to learn more about our AAV Curator Platform: https://buff.ly/4fdrqwO

With over 20 years of experience in cell and gene therapy manufacturing, Andelyn understands how plasmids can impact vector packaging performance. Through a close collaboration between the plasmid and vector teams, clients can leverage our extensive expertise for vector design consultation and optimization. Learn more about our plasmid manufacturing: https://buff.ly/3WUPVqG #AndelynBiosciences #GeneTherapy #PlasmidManufacturing

Stay ahead of the curve in the evolving world of cell and gene therapies with insights from Andelyn Biosciences! Our newsletter is packed with industry updates, expert discussions, and exclusive content. Are you navigating the complexities of plasmid DNA for cell and gene therapy development? In our latest edition, we explore critical factors, from plasmid grade considerations to design optimization in our featured white paper, "Plasmid Optimization for Long-Term Commercial Success," Discover: • The distinctions between research, clinical, and commercial-grade plasmids—and what they mean for your bottom line. • Strategies to streamline manufacturing by understanding plasmid quality standards and regulatory expectations. • Key design considerations to avoid costly production issues and enable sustainable scaling for commercial success. Sign up for our newsletter today to stay up to date on these critical discussions and more: https://buff.ly/3ZRv6zl #AndelynBiosciences #PlasmidOptimization #GeneTherapy #Biopharma #CellAndGeneTherapy #ManufacturingExcellence #Newsletter